搜索结果: 1-15 共查到“医学 the Cancer”相关记录1079条 . 查询时间(0.631 秒)
肢端型黑色素瘤（acral melanoma, AM）是一种起源于手掌、足底和甲下等部位的恶性皮肤肿瘤，也是亚洲人群中最主要的黑色素瘤亚型。原位AM（AM in situ, AMis）突破基底膜进入真皮发展为侵袭性AM（invasive AM, iAM）是造成患者预后变差的重要里程碑事件。然而，目前关于AMis的研究仍然十分有限，AMis向iAM的演化过程尚不清楚，免疫微环境在这一过程中发挥的作用...
肝癌是中国高发恶性肿瘤。由于其广泛的肿瘤异质性，最新的靶向联合免疫治疗的方案仅对20~30%的患者有效，并且缺乏指导精准用药的药敏分子分型。因此亟需研究可以指导肝癌精准用药的分子分型和揭示新的耐药靶点。
近日，首都医科大学基础医学院李长龙副教授团队在《Gastric Cancer》上发表题为“Sustained exposure toHelicobacter pylori induces immune tolerance bydesensitizing TLR6” 的研究论文。该研究揭示了幽门螺杆菌（Hp）持续感染过程中，通过调控宿主胃上皮细胞TLR6/JNK信号通路抑制IL-8分泌，减少中性粒细...
2023年12月2日，国家纳米科学中心聂广军研究员、李素萍研究员团队应邀对肿瘤进展过程中血小板的动态作用及其治疗意义进行了深入探讨和系统总结，相关综述以The dynamic role of platelets in cancer progression and their therapeutic implications为题在线发表于Nature Reviews Cancer期刊（Nature ...
RNA nanoparticle therapy stops the spread of incurable bone marrow cancer（图）
RNA 纳米颗粒疗法 骨髓癌 肿瘤治疗
2023/6/27
Multiple myeloma is an incurable bone marrow cancer that kills over 100,000 people every year. Known for its quick and deadly spread, this disease is one of the most challenging to address. As these c...
Data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer（图）
晚期肺癌 免疫治疗 停止治疗
2023/6/27
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival fo...
In the five years since the FDA’s initial approval of chimeric antigen receptor (CAR) T cell therapy, Penn Medicine has gleaned 20 additional approvals related to drugs and techniques to treat or dete...
Every three to five days, all of the cells lining the human intestine are replaced. That constant replenishment of cells helps the intestinal lining withstand the damage caused by food passing through...
In what may turn out to be a long-missing piece in the puzzle of breast cancer, Harvard Medical School researchers have identified the molecular sparkplug that ignites cases of the disease currently u...
中国科学院上海营养与健康所胡国宏研究员受邀在Cancer Cell上发表研究专评
胡国宏 基因 器官
2023/11/30
2023年5月8日，中国科学院上海营养与健康研究所胡国宏研究员受邀在国际知名学术期刊Cancer Cell上发表题为“A genetic portrait of metastatic seeds in lung adenocarcinoma”的专评文章，对该刊同期发表的一项题为“Genomic mapping of metastatic organotropism in lung adenocar...
近日，中南大学湘雅医院癌变机理与靶向治疗研究中心肖志强教授团队在肿瘤免疫治疗学专业期刊“肿瘤免疫治疗杂志”《J Immunother Cancer》(IF: 12.469)上发表了题为“ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers”的原创...
2023年3月17日，中南大学湘雅医院神经外科主任刘志雄教授团队在《Journal of Experimental and Clinical Cancer Research》（实验与临床癌症研究杂志，中科院一区Top期刊，IF=12.658）在线发表题为“circMMD reduction following tumor treating fields inhibits glioblastoma ...
A novel cancer therapeutic, combining antibody fragments with molecularly engineered nanoparticles, permanently eradicated gastric cancer in treated mice, a multi-institutional team of researchers fou...
周蓉蓉教授团队在国际著名期刊Journal for ImmunoTherapy of Cancer上发表肺腺癌脑转移免疫微环境的原创性科研成果（图）
肿瘤科 国际著名期刊 肺腺癌 肿瘤免疫治疗
2023/5/26
近日，中南大学湘雅医院肿瘤科周蓉蓉教授脑转移MDT团队在国际著名期刊Journal for ImmunoTherapy of Cancer（肿瘤免疫治疗期刊，IF=12.485）以论著形式在线发表了题为“Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negativ...
